Drug Farm Closes $56M Financing
Summary
Drug Farm, a Shangai, China- and Guilford, MA-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, completed financing totaling $56m USD. The company intends to use the funds to initiate human clinical trials with its lead drug DF-006, an orally bioavailable drug for hepatitis B virus (HBV) infection and other liver diseases and to further advance its additional pipeline candidates for therapies in cancer and autoimmune diseases. Led by Dr. Tian Xu, founder and Chairman, and Dr. Henri Lichenstein, CEO and Board Member, Drug Farm is a biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Its IDInVivo platform combines technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems.